ABSTRACT
Diagnosis of a hyper- or hypocoagulable state has been very difficult. The first attempt to solve this problem was the method of endogenous thrombin potential (ETP) by Hemker. In ETP, activators and a chromogenic substrate are added to diluted plasma samples and the thrombin generation is measured. By analysis of acquired data, three characteristics of ETP are seen: lag phase, peak thrombin, and velocity index. ETP is not suited for exact determination of maximum activated thrombin. Therefore, a new method was developed: the thrombin generation assay (THROGA). With the use of THROGA, the maximum generated thrombin in a blood or plasma sample can be measured easily. The background of the method is the addition of a certain amount of recombinant hirudin (r-hirudin) to the blood or plasma sample. After activation, the generated thrombin is bound quantitatively and neutralized by r-hirudin so that at the end of the activation phase the amount of generated thrombin can be determined easily and exactly by measurement of residual r-hirudin in the sample.
KEYWORDS
Thrombin generation assay (THROGA) - thrombin generation capacity - drug monitoring - r-hirudin - global coagulation state
REFERENCES
-
1
Hemker H C, Beguin S.
Thrombin generation in plasma: its assessment via the endogenous thrombin potential.
Thromb Haemost.
1995;
74
134-138
-
2
Nowak G, Wiesenburg A, Schumann A, Bucha E.
Platelet adhesion assay-a new quantitative whole blood test to measure platelet function.
Semin Thromb Hemost.
2005;
31
470-475
Prof. Dr. Götz Nowak
Friedrich Schiller University Jena, Medical Faculty, Research Group “Pharmacological Haemostaseology,” Drackendorfer Str. 1
D-07747 Jena, Germany
Email: AGPHH@med.uni-jena.de
